Structural and Functional Differences Between Glycosylated and Non-glycosylated Forms of Human Interferon-β (IFN-β)

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. Μ., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,446

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,964

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

Girard, M., Duquette, P., & Sibley, W. A. (1993) · Cited by 1,197

The Interferon System

Stewart, W. E. (1979) · Springer eBooks · doi:10.1007/978-3-7091-3432-0 · Cited by 1,165

GLYCOBIOLOGY

Rademacher, T. W., Parekh, R. B., & Dwek, R. A. (1988) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.57.070188.004033 · Cited by 1,144

Protein glycosylation

Lis, H., & Sharon, N. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb18347.x · Cited by 840

The interferon system. A bird's eye view of its biochemistry.

Sen, G. C., & Lengyel, P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42719-6 · Cited by 633

Glycoproteins: what are the sugar chains for?

Paulson, J. C. (1989) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(89)90062-5 · Cited by 461

Influence of the Carbohydrate Moiety on the Stability of Glycoproteins

Wang, C., Eufemi, M., Turano, C., & GIARTOSIO, A. (1996) · Biochemistry · doi:10.1021/bi9517704 · Cited by 344

IFN??-1a Treatment and Reestablishment of Th1 Regulation in MS Patients

Pellegrini, P., Totaro, R., Contasta, I., Berghella, A. M., Russo, T., Carolei, A., & Adorno, D. (2004) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000148387.79476.3f · Cited by 9

Long-term benefits of early and high doses of interferon β-1a treatment in relapsing–remitting multiple sclerosis

Chofflon, M., & Ben-Amor, A.-F. (2002) · Clinical Neurology and Neurosurgery · doi:10.1016/s0303-8467(02)00046-x · Cited by 9

Clinical Applications of Protein-Based Therapeutics

Yadav, M. K., Sahu, A., Anu, Kasturria, N., Priyadarshini, A., Gupta, A. A., Gupta, K., & Tomar, A. K. (2023) · Springer eBooks · doi:10.1007/978-981-19-8249-1_2 · Cited by 8

Maillard reaction and immunogenicity of protein therapeutics

Tsekovska, R., Bozhinov, A., Niwa, T., Ivanov, I., & Mironova, R. (2016) · World Journal of Immunology · doi:10.5411/wji.v6.i1.19 · Cited by 9

Modulating acute neuroinflammation in intracerebral hemorrhage: the potential promise of currently approved medications for multiple sclerosis

Napier, J. A., Rose, L., Adeoye, O. M., Hooker, E. A., & Walsh, K. B. (2019) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2019.1566361 · Cited by 8

Basal buffer systems for a newly glycosylated recombinant human interferon-β with biophysical stability and DoE approaches

Kim, N. A., Song, K., Lim, D. G., Hada, S., Shin, Y. K., Shin, S., & Jeong, S. H. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.07.020 · Cited by 8

Multiple sclerosis

Hawker, K., & Frohman, E. M. (2004) · Primary Care Clinics in Office Practice · doi:10.1016/s0095-4543(03)00123-4 · Cited by 8

Surgical treatment of temporal lobe epilepsy

Berkovic, S. F. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.5.470 · Cited by 8

Therapeutic proteins: facing the challenges of glycobiology

Albrecht, S., Hilliard, M., & Rudd, P. M. (2014) · Journal of Health Policy & Outcomes Research · doi:10.7365/jhpor.2014.5.2 · Cited by 7

Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies

Nguyen, N. H., Jarvi, N. L., & Balu‐Iyer, S. V. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.05.014 · Cited by 7

Validation of a cell-based colorimetric reporter gene assay for the evaluation of Type I Interferons

Mejía‐Calvo, I., Muñoz‐García, L., Jiménez‐Uribe, A. P., Camacho-Sandoval, R., González‐González, E., Mellado‐Sánchez, G., Tenorio-Calvo, A. V., López‐Morales, C. A., Velasco-Velázquez, M. A., Pavón, L., et al. (2019) · Biotechnology Reports · doi:10.1016/j.btre.2019.e00331 · Cited by 7

Stability and Activity of the Hyperglycosylated Human Interferon-β R27T Variant

Song, K., Moon, D. B., Kim, N. Y., & Shin, Y. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-65495-y · Cited by 7

Determination of interferon beta neutralizing antibodies in multiple sclerosis: Improvement of clinical sensitivity of a cytopathic effect assay

Massart, C., Gibassier, J., Seze, J. D., Debouverie, M., Moreau, T., Pelletier, J., Vermersch, P., & Edan, G. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.01.016 · Cited by 7

Early Characterization of Biosimilar Therapeutics

Gelzleichter, T. R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394810-6.00007-1 · Cited by 7

OUP accepted manuscript

Samoudi, M., Minuchehr, Z., Harcum, S. W., Tabandeh, F., Yeganeh, N. O., & Khodabandeh, M. (2016) · Protein Engineering Design and Selection · doi:10.1093/protein/gzw058 · Cited by 7

Preparation of monoPEGylated human interferon beta-1a: Optimization of the conditions for N-terminal PEGylation

Korzhavin, D. V., Chernovskaya, T. V., Efanov, Y. G., Rudenko, E. G., Ivanov, R. A., Pshenichnikova, A. B., & Швец, В. И. (2015) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683815070030 · Cited by 6

Beta interferons from the extant camelids: Unique among eutherian mammals

Premraj, A., Aleyas, A. G., Nautiyal, B., & Rasool, T. J. (2022) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2022.104443 · Cited by 6

Influence of glucose-templated proline mimetics on the β-turn conformation of the peptide fragment Ac-Leu-d-Phe-Pro-Val-NMe2 found in Gramicidin S

Zhang, K., & Schweizer, F. (2010) · Carbohydrate Research · doi:10.1016/j.carres.2010.03.037 · Cited by 6

A modified immune tolerant mouse model to study the immunogenicity of recombinant human interferon beta

Abdolvahab, M. H., Brinks, V., & Schellekens, H. (2014) · Journal of Immunological Methods · doi:10.1016/j.jim.2014.10.004 · Cited by 6

Physiology and Pathology of Cytokine: Commercial Production and Medical Use

Zdravkovic, N. S., Rosic, M. A., Lutovac, M., & Zdravković, V. (2017) · InTech eBooks · doi:10.5772/intechopen.72200 · Cited by 6

Site-specific derivatization of human interferon β-1a at lysine residues using microbial transglutaminase

Spolaore, B., Forzato, G., & Fontana, A. (2018) · Amino Acids · doi:10.1007/s00726-018-2563-1 · Cited by 6

Characterization and minimization of sialic acid degradation in an Fc-fusion protein-producing CHO cell bioprocess

Chen, X., Liu, J., Liu, X., Li, F., Zhao, L., & Tan, W. (2018) · Process Biochemistry · doi:10.1016/j.procbio.2018.08.015 · Cited by 6

Delta-Globin Gene Expression Is Enhanced in vivo by Interferon Type I

Manchinu, M. F., Simbula, M., Caria, C. A., Musu, E., Perseu, L., Porcu, S., Steri, M., Poddie, D., Frau, J., Cocco, E. E., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00163 · Cited by 6

Antiviral and Antiluteolytic Activity of Recombinant Bovine IFN-ω1 Obtained from Pichia pastoris

Boué, O., García, J. L., Villar, M., Alazo, K., Pérez, A. A., Ramos, E., Morales, C., Morera, O. L., Redondo, M., Montero, C., et al. (2000) · Journal of Interferon & Cytokine Research · doi:10.1089/10799900050116372 · Cited by 6

Development of interferon-β as a therapy for multiple sclerosis

Markowitz, C. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.9.2.363 · Cited by 6

Effect of sodium butyrate and zinc sulphate supplementation on recombinant human IFN-β production by mammalian cell culture

Zuqueli, R. P., Prieto, C. C., Etcheverrigaray, M., & Kratje, R. B. (2006) · Latin American Applied Research - An international journal · Cited by 6

Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a

Furber, K. L., Agten, M. V., Evans, C. D., Haddadi, A., Doucette, J. R., & Nazarali, A. J. (2017) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s71986 · Cited by 6

Novel Formulation Approaches for Peptide and Protein Injectables

Yang, M., & Frøkjær, S. (2009) · Wiley eBooks · doi:10.1002/9780470688397.ch2 · Cited by 6

Stability of Polypeptides and Proteins

Dibiase, M., & Kottke, M. (2000) · Drugs and the pharmaceutical sciences · doi:10.1201/b14011-17 · Cited by 6

Increased disulphide dimer formation of latent associated peptide fusions of TGF-β by addition of l-cystine

Mullen, L., Adams, G., & Chernajovsky, Y. (2012) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2012.07.003 · Cited by 5

Recombinant Interferons Beta-1a and Beta-1b: Protein Structural Features and Problematic Issues with Identity Confirmation

Голощапова, Е. О., Рунова, О. Б., & Устинникова, О. Б. (2018) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-018-1892-4 · Cited by 5

Using heat conduction microcalorimetry to study thermal aggregation kinetics of proteins

Zhu, D., Porter, W. R., Long, M. A., Fraunhofer, W., Gleason, K. M., & Gao, Y. Q. (2009) · Thermochimica Acta · doi:10.1016/j.tca.2009.10.012 · Cited by 5

Preventing Aggregation of Recombinant Interferon beta-1b in Solution by Additives: Approach to an Albumin-Free Formulation

Mahjoubi, N., Fazeli, M. R., Dinarvand, R., Khoshayand, M. R., Fazeli, A., Taghavian, M., & Rastegar, H. (2015) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2015.068 · Cited by 5

An Albumin-Free Formulation for Escherichia coli -Derived Interferon Beta-1b with Decreased Immunogenicity in Immune Tolerant Mice

Abdolvahab, M. H., Fazeli, A., Rad‐Malekshahi, M., Nejadnik, M. R., Fazeli, M. R., & Schellekens, H. (2016) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2015.0110 · Cited by 5

Approaches to Managing Protein Aggregation in Product Development

Wang, W., & Warne, N. W. (2010) · Wiley eBooks · doi:10.1002/9780470769829.ch8 · Cited by 5

Protein and Peptide Formulation Development

Ohtake, S., & Wang, W. (2013) · Wiley eBooks · doi:10.1002/9780470571224.pse510 · Cited by 6

Injecting rationale into interferon-β therapy

Reder, A. T., & Antel, J. P. (2000) · Neurology · doi:10.1212/wnl.54.11.2034 · Cited by 5

Cortical bricks and mortar

Ffytche, D. H. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.5.472 · Cited by 5

Deciphering the significant impact of natural glycosylation on human insulin

Li, Y., Liu, W., Liu, D., Wang, R., Zhang, Y., Li, X., Gong, J., Shang, S., & Tan, Z. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.08.005 · Cited by 4

Molecular Variants Characterization in Protein Therapeutics Development

Ludwig, R. T., Bongers, J., Tao, L., Huang, Y., Fu, J., Wu, W., Liu, P., Song, H., & Russell, R. J. (2013) · Springer eBooks · doi:10.1007/978-1-4419-7862-2_6 · Cited by 4

Establishment of serum-free adapted Chinese hamster ovary cells with double knockout of GDP-mannose-4,6-dehydratase and GDP-fucose transporter

Misaki, R., Iwasaki, M., Takechi, H., Yamano, N., Ohashi, T., Kajiura, H., & Fujiyama, K. (2022) · Cytotechnology · doi:10.1007/s10616-021-00501-3 · Cited by 4

The Structure of Human Interferon-b-1a (Avonex1®) and its Relation to Activity

Whitty, A., & Karpusas, M. (2003) · CRC Press eBooks · doi:10.1201/9780203911327.ch18 · Cited by 4

Biological Functions of Interferon β-1a Are Enhanced By Deamidation

Mastrangeli, R., Iozzino, L., Lanzoni, L., Angiuoni, G., Ferrao, C., Izzo, A., Fiumi, S., Camerini, F., Mascia, M., Palinsky, W., et al. (2016) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2016.0025 · Cited by 4

[Interferon beta as a therapy for múltiple sclerosis]

García, F., & Lorente, M. I. (2002) · PubMed · Cited by 4

Pharmacokinetics Versus In Vitro Antiproliferative Potency to Design a Novel Hyperglycosylated hIFN-α2 Biobetter

Gugliotta, A., Leopold, M. J., Mufarrege, E. F., Etcheverrigaray, M., Kratje, R. B., Ceaglio, N., & Oggero, M. (2021) · Pharmaceutical Research · doi:10.1007/s11095-020-02978-7 · Cited by 4

Features of the solubilization of interferon beta-1B from inclusion bodies

Zhuravko, A. S., Kononova, N. V., & Bobruskin, A. I. (2015) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162015040159 · Cited by 4

Expression of human interferon β in mammary glands of transgenic rabbits

Khodarovich, Y. M., Vorobyeva, N. E., Мезина, М. Н., Pinyugina, M. V., Прокофьев, М. И., & Larionov, O. A. (2008) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162008020052 · Cited by 4

Clinical trial methodology

Cohen, J. A., & Rudick, R. A. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9781139023986.009 · Cited by 4

Biotechnology and drugs

Parker, M., & Li, Z. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00022-2 · Cited by 4

Co-expression of human sialyltransferase improves N-glycosylation in Leishmania tarentolae and optimizes the production of humanized therapeutic glycoprotein IFN-beta

Senra, R. L., Pereira, H. S., Schittino, L. M. P., Fontes, P. P., de Oliveira, T. A., Ribon, A. D. O. B., Fietto, J. L. R., Felicori, L. F., Fiuza, J. A., & Mendes, T. A. D. O. (2024) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2024.08.002 · Cited by 3

Site Directed Disulfide PEGylation of Interferon-β-1b with Fork Peptide Linker

Abbasi, S., Farahani, H., Lanjanian, H., Taheri, M. N., Firoozpour, L., Davoodi, J., Pirkalkhoran, S., Riazi, G. H., & Pooyan, S. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00839 · Cited by 3

Lower leukocytes pretreatment as a possible risk factor for therapy-induced leukopenia in interferon-beta-treated patients with multiple sclerosis

Protopapa, M., Schmaul, S., Schraad, M., Pape, K., Zipp, F., Bittner, S., & Uphaus, T. (2024) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864241286497 · Cited by 3

Design, Construction and Expression of a Synthetic β-Interferon (IFN-β) Gene in E. coli

Ghane, M., Yakhchali, B., Khodabandeh, M., & Malekzadeh, F. (2006) · Pakistan Journal of Biological Sciences · doi:10.3923/pjbs.2006.2922.2926 · Cited by 3

Review, Approval, and Marketing of Biosimilars in the United States Part 1: Safety and Regulatory Issues

Aagaard, A. W., Purdy, S., & Philpott, S. M. (2010) · Cited by 3

Cell‐Based Assays for the Detection of Neutralizing Antibodies to Interferon Beta (IFN‐β) and Tumor Necrosis Factor Alpha (TNF‐α) Inhibitors

Meager, A. (2011) · doi:10.1002/9781118075685.ch8 · Cited by 3

Subcutaneous suspensions of therapeutic proteins formulated as protein-coated microcrystals

Berkenhoff, K. (2013) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.15710 · Cited by 3

Behandlung der schubförmigen Multiplen Sklerose mit rekombinanten Interferon-β-Präparaten

Mäurer, M., Gold, R., Toyka, K. V., & Rieckmann, P. (2001) · Der Nervenarzt · doi:10.1007/s001150050722 · Cited by 3

Natural And Induced Anticytokine Antibodies In Humans

Svenson, M., Bendtzen, K., Meyer, C. G., Ross, C., & Hansen, M. B. (2000) · CRC Press eBooks · doi:10.1201/9780203904244.ch3 · Cited by 3

Development of a Hyperglycosylated IFN Alfacon-1 (CIFN): Toward Bimonthly or Monthly Dosing for Antiviral Therapies

Taylor, J. S., Zhang, Q., Julander, J. G., Stoycheva, A. D., Tan, H. T., Moy, C. V., Chanda, S. M., Symons, J. A., Beigelman, L. N., Blatt, L. M., et al. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0138 · Cited by 2

Molecular Docking, Dynamics, and WaterSwap Analysis to Identify Anti-aggregating Agents of Insulin and IFN-β

Sharma, P., Raju, B., Narendra, G., Sapra, B., & Silakari, O. (2022) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-022-03881-0 · Cited by 2

Challenges with the biophysical characterization of complex (multi-chain assembly, chemically modified, big and high concentration) biopharmaceuticals

Berkowitz, S. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-444-64173-1.00015-9 · Cited by 2

Molecular characterization of novel variants of interferon-tau (IFNT) gene in Garole breed of sheep (Ovis aries)

Rajaravindra, K. S., Das, P. J., Kandasamy, S., Ghosh, S. K., & Mitra, A. (2007) · Animal Reproduction Science · doi:10.1016/j.anireprosci.2007.02.012 · Cited by 2

Interferon-β1a: a once-weekly immunomodulatory treatment for patients with multiple sclerosis

Kinkel, R. P. (2006) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2.5.691 · Cited by 2

Gene transplantation: combined antisense inhibition and gene replacement strategies.

Robinson‐Benion, C., Li, Y. X., & Holt, J. T. (1994) · PubMed · Cited by 2

Impact of Glycosylation on Therapeutic Glycoproteins

Mousavi, M., Dehbashi, M., & Movahedi, A. (2016) · British Journal of Applied Science & Technology · doi:10.9734/bjast/2016/29679 · Cited by 1

Toward N-Linked Glycoproteins: Three-Step Synthesis of Glycan-Asparagine Conjugates from Unprotected Sugars

Akeno, J., Takasu, K., Oisaki, K., Nozawa‐Kumada, K., Sada, H., Nanjo, T., Fukaya, N., & Ueda, Y. (2026) · Organic Letters · doi:10.1021/acs.orglett.6c00314 · Cited by 1

Analisi Costo Minimizzazione delle preparazioni di Interferon Beta per il trattamento della Sclerosi Multipla

Macchia, F., Russo, P., & Caprino, L. (2004) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v5i2.789 · Cited by 1

Different Interferon Beta Preparations Induce the Same Qualitative Immune Response in Human Skin

Hermanrud, C. E., van Capel, T. M. M., Auer, M., Karrenbauer, V. D., Deisenhammer, F., de Jong, E. C., & Fogdell‐Hahn, A. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0038 · Cited by 1

Development and certification of a pharmacopoeial reference standard for primary structure identification of purified recombinant interferon beta-1b by peptide mapping

Голощапова, Е. О., Rounova, O. B., Минеро, А. С., Фадейкина, О. В., Волкова, Р. А., Degterev, M. B., Taran, S., Shukurov, R. R., & Устинникова, О. Б. (2022) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2022-22-1-23-37 · Cited by 1

Bioprocess optimization of interferon β-1-a in Pichia pastoris and its improved inhibitory effect against hepatocellular carcinoma cells

Moatamedi, N., Emamzadeh, R., Hamid, M., & Akbari, V. (2022) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902022e18984 · Cited by 1

Interferons

Degrave, W. M. S., & Mendonça-Lima, L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-444-63660-7.00003-6 · Cited by 1

Molecular characterization of IFN-T expressed in buffalo embryonic trophoblasts and expression of recombinant BuIFN-T1a2 and BuIFN-T8 isoforms in E. coli

Saugandhika, S., Sharma, V., Malik, H. N., Mohapatra, S. K., Bondre, V. P., Kumar, S., Mohanty, A. K., & Malakar, D. (2016) · Protein Expression and Purification · doi:10.1016/j.pep.2016.02.005 · Cited by 1

Antibody-drug discovery

Blass, B. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817214-8.00009-9 · Cited by 1

Use of Anti‐Interferon Beta Antibody Measurements in Multiple Sclerosis

Sørensen, P. S., Deisenhammer, F., Duda, P. W., Hohlfeld, R., Myhr, K., Palace, J. A., Polman, C. H., Pozzilli, C., & Ross, C. (2010) · doi:10.1002/9781444328394.ch5 · Cited by 1

Immunological aspects of antibody formation against recombinant human therapeutics

Sauerborn, M. (2010) · Utrecht University Repository (Utrecht University) · Cited by 1

Stability Assessment and Formulation Characterization

Chow, A. H. L., Tong, H. H. Y., & Zheng, Y. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse301 · Cited by 1

Interferons in the Treatment of Multiple Sclerosis: Errors and Misrepresentations

Herndon, R. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.3.426 · Cited by 1

Use of Anti‐Interferon Beta Antibody Measurements in Multiple Sclerosis

Sørensen, P. S., Deisenhammer, F., Duda, P. W., Hohlfeld, R., Myhr, K., Palace, J. A., Polman, C. H., Pozzilli, C., & Ross, C. (2006) · doi:10.1002/9780470753279.ch8 · Cited by 1

Immunogenicity of Therapeutic Proteins and the Assessment of Risk

Schellekens, H., & Jiskoot, W. (2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse179

Detection of Neutralizing Antibodies against Interferon Beta by Real‐Time RT‐PCR

Gilli, F., & Bertolotto, A. (2011) · doi:10.1002/9781118075685.ch9

ANTI-DRUG ANTIBODIES IN PATIENTS WITH MULTIPLE SCLEROSIS

Ryner, M. L. (2013) · Figshare

Role of type I Interferons in the treatment of endocrine and non-endocrine cancers

Vitale, G. (2006) · Università degli Studi di Napoli Federico II · doi:10.6092/unina/fedoa/785

Neutralisierende Antikörper gegen Interferon-beta in der Therapie der Multiplen Sklerose/Neutralizing Antibodies against Interferon-Beta in the Treatment of Multiple Sclerosis

Gneiss, C., & Deisenhammer, F. (2003) · Journal of Laboratory Medicine · doi:10.1515/labmed.2003.047

Hippocampal atrophy and neocortical dysfunction in early Alzheimer's disease

Baron, J. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.5.470-a

Interferon-β1atreatment for multiple sclerosis

Sandberg‐Wollheim, M. (2005) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.5.1.25

A Novel Selection Technology for the Discovery of High-Affinity Human Proteins

Busha, D. A. (2014) · CU Scholar (University of Colorado Boulder)

Chemical Structure of DNA

Butola, Revathi, B., Anila, G., & Kumar, S. (2016) · Research and reviews : journal of chemistry

New ultra scale-down principles for monoclonal antibody recovery and purifications

Hutchinson, N. (2007) · Doctoral thesis, University of London.

Peptides, Proteins and Antibodies

Lalatsa, A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-9164-4_19

Synthesis of N-Linked Glycopeptides Using Convergent Enzymatic Glycosylation Combined with SPPS

Kowalczyk, R., Kaur, H., Fairbanks, A. J., & Brimble, M. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-65587-1_1

In Silico and In Vitro Investigations On Mutated IFNβ-scFv Against Human Collagen Type IIPreprint

Alimohammadi, F., Hojati, Z., & Ganjalıkhani-Hakemi, M. (2021) · Research Square · doi:10.21203/rs.3.rs-987486/v1

Immunogenicity considerations

(2015) · CRC Press eBooks · doi:10.1201/b19077-3

Asn25 Deamidation as an Allosteric Tool to Increase IFNβ-1a Biological Activity

Lipari, E., Saporiti, S., Eberini, I., Massimo, L., Mazzarella, E., Anderloni, G., Rossi, M., D'Amici, F., Pergola, C., Palinsky, W., et al. (2022) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2021.0209

Molecular Farming

Mäntylä, E., & Örvar, B. L. (2014) · Biotechnology in agriculture and forestry · doi:10.1007/978-3-662-44406-1_13

BETAFERON'UN COVID-19 İÇİN ANTİVİRAL AKTİVİTESİ

Bayrakdar, F., Özkan, S. A., & Akçalı, K. C. (2022) · Ankara Universitesi Eczacilik Fakultesi Dergisi · doi:10.33483/jfpau.1112165

Fine-Tuning the Immune Response Against Cancer with Antibody-Cytokine Fusion Proteins

Ferrero, S., Gatto, M. I., & Helguera, G. F. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_201-1

Peptides, Proteins and Antibodies

Gennaro, S. I. D., & Lalatsa, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-59478-6_19

Glycosylation-enabled Site-specific Growth Factor Engineering for Biomaterial FunctionalizationPreprint

Xing, Y., Li, Q., Campbell, P. G., & Ren, X. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.11.652418

Fine-Tuning the Immune Response Against Cancer with Antibody-Cytokine Fusion Proteins

Ferrero, S., Gatto, M. I., & Helguera, G. F. (2025) · Springer eBooks · doi:10.1007/978-3-032-00767-4_201

Mutant p53 gain-of-function and immune suppression: Mathematical modeling of STING–TBK1–IRF3 axis restoration for enhanced cancer therapy

Omer, S., Ouifki, R., & Mambili‐Mamboundou, H. (2026) · Mathematical Biosciences · doi:10.1016/j.mbs.2026.109806

In vitro biological characterization of IFN- -1a major glycoforms

Mastrangeli, R., Rossi, M., Mascia, M., Palinsky, W., Datola, A., Terlizzese, M., & Bierau, H. (2014) · Glycobiology · doi:10.1093/glycob/cwu082 · Cited by 14

The Function of the Human Interferon-β1a Glycan Determined in Vivo

Dissing‐Olesen, L., Thaysen‐Andersen, M., Meldgaard, M., Højrup, P., & Finsen, B. R. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.138263 · Cited by 40

Human Interferon-Beta: Effects of Deglycosylation

Knight, E., & Fahey, D. (1982) · Journal of Interferon Research · doi:10.1089/jir.1982.2.421 · Cited by 32

The structure of human interferon- ? : implications for activity

Karpusas, M., Whitty, A., Runkel, L., & Hochman, P. S. (1998) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050248 · Cited by 111

DEVELOPMENT AND QUALIFICATION OF BIOANALYTICAL METHODS FOR DEAMIDATED IFNβ-1a AND INVESTIGATION ABOUT THE MECHANISM OF ACTION

Lipari, E. (2021) · Nova Science Publishers (Nova Science Publishers, Inc.)